SCHEMBL5543812

SCHEMBL5543812

O=CCCSc1cccc(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.40
DHFR P00374 1/20 0.40
TERT O14746 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
GRM5 P41594 1/20 0.38
ALPG P10696 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAOA P21397 1/20 0.36
TRPM5 Q9NZQ8 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 3/20 0.36
GAA P10253 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HTT P42858 2/20 0.35
MAPK1 P28482 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30753710 0.82 ALDH1A1 (0.50) MAOBDHFRTDP1GRM5ALPG
SCHEMBL5544877 0.79 MAOA (0.36) MAOBL3MBTL1MAOAGAASLC6A2
SCHEMBL5043256 0.77 KIF11 (0.49) MAOBDHFRTDP1GRM5ALPG
SCHEMBL5542119 0.77 KDM4E (0.47) TDP1L3MBTL1POLBMAPTHTT
SCHEMBL949802 0.77 ALDH1A1 (0.61) GAAMAPK1MEN1KMT2AALDH1A1
SCHEMBL12879673 0.76 GRM5 (0.44) MAOBDHFRTDP1GRM5ALPG
SCHEMBL30487707 0.76 GRM5 (0.44) MAOBDHFRTDP1GRM5ALPG
SCHEMBL9621723 0.75 KDM4E (0.49) L3MBTL1POLBMAPTGAASLC6A2
SCHEMBL28364062 0.74 TDP1 (0.45) MAOBDHFRTDP1GRM5ALPG
SCHEMBL27650757 0.74 TAAR1 (0.55) MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOB 2140/4885DHFR 180/4885TERT 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.